News · Healthcare & Life Sciences

Biodimension builds human tissue alternatives to animal testing

By Startup Enthusiast · 29 August 2026

What they do

Biodimension makes reconstructed human tissues and organoids for drug discovery and cosmetics testing

The Bengaluru startup uses human cells on biomaterial scaffolds to create skin models and miniature organs

Its technology aims to replace animal testing, which fails to predict human responses accurately

Biodimension was founded in 2021 in Bengaluru.
The startup builds human-relevant alternatives to animal testing.
It uses reconstructed human tissues and organoids (miniature versions of organs made from patient cells).
Its technology is applied in drug discovery, pharmaceutical research, cosmetics, and personal care.
The company has a 6,000-square-foot NAMs facility (new approach methodologies) in Bengaluru.
Biodimension is working towards OECD Test Guidelines but currently limits its scope to research use.

About 90% of drugs entering human trials fail because animal models don't predict human response accurately.
The current testing system cannot represent human biology adequately.
Biodimension started with skin models due to regulatory pressure in cosmetics and personal care to end animal testing.

Biodimension creates reconstructed human tissues using human cells on biomaterial scaffolds like collagen and gelatin.
Its skin models are grown with an air-exposed top surface to mimic the skin's barrier function.
Organoids self-organise from patient cells into miniature versions of tumours or organs.
Validation involves three levels: structural (correct layers and proteins), functional (reference chemicals), and statistical (repeated batches with reported variation).
The technology serves drug discovery, pharmaceutical research, cosmetics, and personal care industries.

Biodimension is working towards OECD Test Guidelines for regulatory acceptance.
Currently its products are for research use only.

Product: Human tissue models, organoids, and bioassay-as-a-service including BioDEpi, BioDFT, BioDPigma and pan-cancer tumor microenvironment biobank
Customers: Pharmaceutical, biotechnology and cosmetic companies requiring safety testing
How it makes money: Bioassay-as-a-service and licensing of tissue models
What sets it apart: Lab-grown tissue models that accurately replicate human responses for drug testing
Operations: Laboratory infrastructure for tissue fabrication and testing services